KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - AccuredRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Twist Bioscience (TWST) Accumulated Expenses (2018 - 2025)

Twist Bioscience (TWST) has disclosed Accumulated Expenses for 8 consecutive years, with $23.4 million as the latest value for Q4 2025.

  • Quarterly Accumulated Expenses rose 16.28% to $23.4 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $23.4 million through Dec 2025, up 16.28% year-over-year, with the annual reading at $23.1 million for FY2025, 31.49% down from the prior year.
  • Accumulated Expenses for Q4 2025 was $23.4 million at Twist Bioscience, up from $23.1 million in the prior quarter.
  • The five-year high for Accumulated Expenses was $33.6 million in Q3 2024, with the low at $6.4 million in Q3 2021.
  • Average Accumulated Expenses over 5 years is $20.2 million, with a median of $21.2 million recorded in 2022.
  • The sharpest move saw Accumulated Expenses surged 319.81% in 2022, then plummeted 60.2% in 2023.
  • Over 5 years, Accumulated Expenses stood at $11.7 million in 2021, then skyrocketed by 99.19% to $23.3 million in 2022, then decreased by 10.7% to $20.8 million in 2023, then fell by 3.17% to $20.1 million in 2024, then rose by 16.28% to $23.4 million in 2025.
  • According to Business Quant data, Accumulated Expenses over the past three periods came in at $23.4 million, $23.1 million, and $29.0 million for Q4 2025, Q3 2025, and Q2 2025 respectively.